Results 151 to 160 of about 125,339 (239)

GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory. [PDF]

Compr Physiol
Gao SX, Décarie-Spain L, Gu C, Mazzini G, Kanoski SE, Borner T.   +5 more
europepmc   +1 more source

Advances in GPCRs Associated With Wnt Signaling Within the Auditory System

Medicine Bulletin, EarlyView.
ABSTRACT G protein‐coupled receptors (GPCRs) that interact with the Wnt signaling pathway are pivotal for auditory system homeostasis, as they orchestrate inner ear development, hair cell (HC) regeneration, and hearing preservation. Frizzled (FZD) receptors, the core Wnt‐related GPCRs, bind Wnt ligands and co‐receptors (e.g., LRP5/6) to activate both ...
Liang Wang, Changling Xu, Jiangang Fan, Renjie Chai   +3 more
wiley   +1 more source

The brain geography of GLP-1: An atlas for a new era. [PDF]

Brain Med
Licinio J, Wong ML.
europepmc   +1 more source

Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists

iNew Medicine, EarlyView.
Chao Xue
wiley   +1 more source

The Effect of GLP-1 Receptor Agonists on Epilepsy: No Appetite for Seizures. [PDF]

Epilepsy Curr
Karakis I.
europepmc   +1 more source

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

Med Research, EarlyView.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang, Diyuan Zhang, Yuqin Zhou, Ling Qian, Yan Wang, Lei Peng, Min Zhao, Hao Tian, Zhenyu Wu, Aiqi Tang, Minghao Sun, Yi Zhang, Xiaowei Qi   +12 more
wiley   +1 more source

Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study. [PDF]

J Transl Med
Korus S, Cembrowska-Lech D, Kłoda K, Stachowska E.   +3 more
europepmc   +1 more source

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

Med Research, EarlyView.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists. [PDF]

Genome Med
Umapathysivam MM, Araldi E, Hastoy B, Dawed AY, Vatandaslar H, Mayrhofer JE, Lindquist P, Silva PN, Goga A, Trüllinger GO, Godbersen S, Sengupta S, Kaufmann A, Thomsen SK, Hartmann B, Chen YC, Jonsson AE, Kabakci H, Thaman S, Grarup N, Have CT, Pallo LP, Faerch K, Gjesing AP, Nawaz S, Cheeseman J, Neville MJ, Pedersen O, Walker M, Sun H, Jennison C, Hattersley AT, Rehfeld JF, Holman RR, Verchere BC, Hansen T, Karpe F, Holst JJ, Rosenkilde MM, Jones AG, Ristow M, McCarthy MI, Pearson ER, Stoffel M, Gloyn AL.   +44 more
europepmc   +1 more source

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

Movement Disorders, EarlyView.
Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David‐Erick Lafontant, Seyed‐Mohammad Fereshtehnejad, Yashar Zeighami, Piergiorgio Grillo, Giulietta M. Riboldi, Houman Azizi, Roqaie Moqadam, Un Jung Kang, Kelly N.H. Nudelman, Andrew Siderowf, Caroline M. Tanner, Thomas F. Tropea, Tatiana Foroud, Lana M. Chahine, Brit Mollenhauer, Kalpana M. Merchant, Douglas Galasko, Christopher S. Coffey, Roseanne D. Dobkin, Ethan G. Brown, Roy N. Alcalay, Daniel Weintraub, Kenneth Marek, Tanya Simuni, Paulina Gonzalez‐Latapi, Nicola Pavese, Kathleen L. Poston, the Parkinson's Progression Markers Initiative   +30 more
wiley   +1 more source